Li LiQi, Zheng YuHong, Li JiaXin, Zhao Lin, Lin Xin, Zhang Hao, Chen HuiHui, Yan PeiYu
Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau 999078, China; Zhuhai MUST Science and Technology Research Institute, Zhuhai 519031, China.
Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau 999078, China; Zhuhai MUST Science and Technology Research Institute, Zhuhai 519031, China.
J Ayurveda Integr Med. 2026 Mar 12;17(2):101242. doi: 10.1016/j.jaim.2025.101242.
The incidence of pulmonary diseases remains unacceptably high, underscoring the need for improved therapeutic strategies. The current therapeutic landscape, largely reliant on antibiotics and hormonal agents, is constrained by growing challenges such as drug resistance, significant toxicity profiles, and prolonged disease courses. As a time-honored TCM prescription, Weijing Decoction (WJD) is widely administered for respiratory ailments. However, a critical appraisal of the existing literature reveals a paucity of high-quality evidence. Research to date has largely been confined to anecdotal case reports or preliminary investigations with limited sample sizes, resulting in a lack of systematic assessment on the combined efficacy and safety of WJD and modern medical interventions.
This study aimed to systematically evaluate and meta-analyze the therapeutic efficacy of Weijing Decoction (WJD) in the management of respiratory diseases, including chronic obstructive pulmonary disease (COPD) and pneumonia.
A comprehensive literature search was conducted across six electronic databases, including both international and Chinese-language databases, to identify randomized controlled trials (RCTs) evaluating the efficacy of WJD in the treatment of COPD and pneumonia. Data on primary outcomes, including the overall clinical efficacy rate, C-reactive protein (CRP) levels, and Traditional Chinese Medicine Syndrome Scores, were extracted and synthesized using RevMan version 5.4 software. Statistical heterogeneity across studies was assessed using the I test and Chi-square test. A fixed-effect model was employed in the presence of low heterogeneity (I ≤ 50 %, p > 0.1), whereas a random-effects model was applied when significant heterogeneity was observed (I > 50 %, p < 0.1). Funnel plots were used to assess potential publication bias among the included studies.
A total of 10 eligible studies involving 1315 patients diagnosed with respiratory diseases were included in the analysis. Patients in the control group received conventional medical treatment, whereas those in the intervention group received WJD in addition to standard therapy. The intervention group demonstrated significantly higher overall disease efficacy rates, along with marked reductions in CRP levels and lower Traditional Chinese Medicine Syndrome Scores (including symptoms such as cough and sputum production), compared to the control group (all p < 0.05).
The combination of WJD with conventional therapy appears to be an effective and beneficial treatment strategy for managing COPD and pneumonia, potentially improving clinical outcomes. This integrative approach shows promise in enhancing the quality of care and may offer additional therapeutic advantages in the management of these respiratory conditions.
肺部疾病的发病率仍然高得令人难以接受，这凸显了改进治疗策略的必要性。目前的治疗格局很大程度上依赖于抗生素和激素类药物，但受到诸如耐药性、显著的毒性特征以及病程延长等日益严峻的挑战的限制。作为一个历史悠久的中药方剂，苇茎汤（WJD）被广泛用于治疗呼吸系统疾病。然而，对现有文献的批判性评估发现高质量证据匮乏。迄今为止的研究主要局限于轶事性病例报告或样本量有限的初步调查，导致缺乏对苇茎汤与现代医学干预措施联合使用的疗效和安全性的系统评估。
本研究旨在系统评价和荟萃分析苇茎汤（WJD）治疗包括慢性阻塞性肺疾病（COPD）和肺炎在内的呼吸系统疾病的疗效。
在包括国际数据库和中文数据库在内的六个电子数据库中进行全面的文献检索，以识别评估苇茎汤治疗COPD和肺炎疗效的随机对照试验（RCT）。使用RevMan 5.4版软件提取并综合主要结局的数据，包括总体临床有效率、C反应蛋白（CRP）水平和中医证候评分。使用I²检验和卡方检验评估各研究之间的统计异质性。当异质性较低（I²≤50%，p>0.1）时采用固定效应模型，而当观察到显著异质性（I²>50%，p<0.1）时应用随机效应模型。采用漏斗图评估纳入研究中潜在的发表偏倚。
共有10项符合条件的研究纳入分析，涉及1315例被诊断为呼吸系统疾病的患者。对照组患者接受常规医学治疗，而干预组患者在标准治疗的基础上接受苇茎汤治疗。与对照组相比，干预组的总体疾病有效率显著更高，同时CRP水平显著降低，中医证候评分更低（包括咳嗽和咳痰等症状）（所有p<0.05）。
苇茎汤与传统疗法联合使用似乎是治疗COPD和肺炎的一种有效且有益的治疗策略，可能改善临床结局。这种综合方法在提高护理质量方面显示出前景，并且在这些呼吸系统疾病的管理中可能提供额外的治疗优势。
